EA202190335A1 - Композиции антител против fcrn и способы их применения - Google Patents
Композиции антител против fcrn и способы их примененияInfo
- Publication number
- EA202190335A1 EA202190335A1 EA202190335A EA202190335A EA202190335A1 EA 202190335 A1 EA202190335 A1 EA 202190335A1 EA 202190335 A EA202190335 A EA 202190335A EA 202190335 A EA202190335 A EA 202190335A EA 202190335 A1 EA202190335 A1 EA 202190335A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- application
- antibody compositions
- compositions against
- against fcrn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701467P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042597 WO2020023310A1 (en) | 2018-07-20 | 2019-07-19 | Compositions of fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190335A1 true EA202190335A1 (ru) | 2021-06-11 |
Family
ID=69180697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190335A EA202190335A1 (ru) | 2018-07-20 | 2019-07-19 | Композиции антител против fcrn и способы их применения |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210299255A1 (enExample) |
| EP (1) | EP3826641A4 (enExample) |
| JP (1) | JP7457704B2 (enExample) |
| KR (1) | KR20210105872A (enExample) |
| CN (1) | CN113301903A (enExample) |
| AU (1) | AU2019312139B2 (enExample) |
| BR (1) | BR112021001017A2 (enExample) |
| CA (1) | CA3106669A1 (enExample) |
| CR (1) | CR20210088A (enExample) |
| EA (1) | EA202190335A1 (enExample) |
| IL (1) | IL280280B2 (enExample) |
| JO (2) | JOP20210015A1 (enExample) |
| MX (1) | MX2021000790A (enExample) |
| PH (1) | PH12021550096A1 (enExample) |
| SG (1) | SG11202100420UA (enExample) |
| WO (1) | WO2020023310A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| IL302516A (en) * | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
| US20240182598A1 (en) * | 2021-04-12 | 2024-06-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating pediatric myasthenia gravis |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| CN116539488B (zh) * | 2023-05-11 | 2023-11-24 | 中国食品药品检定研究院 | 一种体外评价生物制品稳定性的方法、系统及设备 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2026083290A1 (en) | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03504499A (ja) * | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| CN101721362B (zh) * | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| US20110027267A1 (en) * | 2007-11-09 | 2011-02-03 | Anaphore, Inc. | Fusion Proteins of Mannose Binding Lectins for Treatment of Disease |
| WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| WO2017015622A2 (en) * | 2015-07-22 | 2017-01-26 | Scholar Rock, Inc | Gdf11 binding proteins and uses thereof |
| SMT202400004T1 (it) * | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
-
2019
- 2019-07-19 WO PCT/US2019/042597 patent/WO2020023310A1/en not_active Ceased
- 2019-07-19 MX MX2021000790A patent/MX2021000790A/es unknown
- 2019-07-19 IL IL280280A patent/IL280280B2/en unknown
- 2019-07-19 BR BR112021001017-3A patent/BR112021001017A2/pt unknown
- 2019-07-19 KR KR1020217003706A patent/KR20210105872A/ko not_active Abandoned
- 2019-07-19 JO JOP/2021/0015A patent/JOP20210015A1/ar unknown
- 2019-07-19 CN CN201980061788.8A patent/CN113301903A/zh active Pending
- 2019-07-19 PH PH1/2021/550096A patent/PH12021550096A1/en unknown
- 2019-07-19 EP EP19840439.4A patent/EP3826641A4/en not_active Withdrawn
- 2019-07-19 CA CA3106669A patent/CA3106669A1/en active Pending
- 2019-07-19 CR CR20210088A patent/CR20210088A/es unknown
- 2019-07-19 JP JP2021526403A patent/JP7457704B2/ja active Active
- 2019-07-19 JO JOP/2021/0014A patent/JOP20210014A1/ar unknown
- 2019-07-19 US US17/260,318 patent/US20210299255A1/en active Pending
- 2019-07-19 SG SG11202100420UA patent/SG11202100420UA/en unknown
- 2019-07-19 AU AU2019312139A patent/AU2019312139B2/en active Active
- 2019-07-19 EA EA202190335A patent/EA202190335A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL280280B2 (en) | 2024-11-01 |
| AU2019312139A1 (en) | 2021-02-04 |
| JP7457704B2 (ja) | 2024-03-28 |
| WO2020023310A1 (en) | 2020-01-30 |
| JP2021531346A (ja) | 2021-11-18 |
| CA3106669A1 (en) | 2020-01-30 |
| IL280280A (en) | 2021-03-25 |
| MX2021000790A (es) | 2021-07-21 |
| JOP20210015A1 (ar) | 2021-01-19 |
| PH12021550096A1 (en) | 2022-03-28 |
| EP3826641A4 (en) | 2022-04-20 |
| IL280280B1 (en) | 2024-07-01 |
| AU2019312139B2 (en) | 2025-02-06 |
| KR20210105872A (ko) | 2021-08-27 |
| JOP20210014A1 (ar) | 2021-01-19 |
| US20210299255A1 (en) | 2021-09-30 |
| CR20210088A (es) | 2021-09-02 |
| BR112021001017A2 (pt) | 2021-05-04 |
| SG11202100420UA (en) | 2021-02-25 |
| EP3826641A1 (en) | 2021-06-02 |
| CN113301903A (zh) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190335A1 (ru) | Композиции антител против fcrn и способы их применения | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| MY193353A (en) | Anti-vegf protein compositions and methods for producing the same | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| UA130214C2 (uk) | Фармацевтична композиція антитіл проти fcrn | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| PE20091205A1 (es) | Anticuerpo anti-receptor de il-6 | |
| AR095614A1 (es) | Anticuerpos heterodiméricos biespecíficos | |
| EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
| PE20141658A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| EA200900037A1 (ru) | Моноклональные антитела против интерлейкина-6 (il-6) и их применение | |
| MX2022001111A (es) | Anticuerpo anti-pd-1 y uso farmaceutico del mismo. | |
| MX2020012350A (es) | Anticuerpos anti-cd63, conjugados y usos de estos. | |
| JOP20210093B1 (ar) | جسم مضاد fn14 غير متوافق مع الإنسان | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| PE20230075A1 (es) | Anticuerpos anti-flt3 y composiciones | |
| EA202092612A1 (ru) | Способ ферментативного дегуммирования масла | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA202092069A1 (ru) | Композиции и способы лечения макулярной дистрофии |